A Nigeria launch fails more often at “dossier engineering” than at product
selection.
@media{@media{.o_basic_theme
div.o_apple_wrapper_padding{padding:0px;}}}@media(min-width:737px){@media{@media{.o_basic_theme
div.o_apple_wrapper_padding{padding-left:34px;}}}}
Hi Srushti Pharamaceuticals Private Limited
If Nigeria is on your 2026 Africa roadmap, here’s a reality check that saves
time and prevents “avoidable” NAFDAC loops.
NAFDAC has steadily moved the market toward CTD-first discipline*—and it’s not
just a formatting preference. CTD has been formally implemented as theor
submissions, and exporters who treat it as a last-minute rearrangement usually
pay for it in queries and rework.
Five Nigeria-specific signals we’re seeing from NAFDAC’s own guidance:*
CTD is the baseline:* NAFDAC has published dossier guidance in CTD form and
announced full CTD implementation (effective June 1, 2020).
Imported products face structured scrutiny:* NAFDAC’s imported drug guideline
(updated Jan 2025) explicitly calls out CTD dossier submission and expectations
around BE/biowaiver evidence for generics.
Pre-submission meetings exist:* NAFDAC introduced pre-submission meetings for
CTD dossiers (a strong hint that “first-time-right” planning is being rewarded).
Timelines assume completeness:* NAFDAC’s own service information indicates drug
registrations are processed within stated working-day timelines from acceptance
of a complete application—so dossier readiness is the real lever, not just
follow-ups.
Guidelines refresh frequently:* NAFDAC’s regulatory resources page shows
2024–2025 guideline updates—meaning Nigeria planning needs active tracking, not
a one-time checklist.
Why this matters for your Nigeria expansion*
Most delays aren’t because the product is “wrong.” They happen because the
dossier ecosystem (COAs, specs, stability, GMP/CoPP, Module-to-Module
consistency, labeling/claims) isn’t engineered as one consistent story before
submission.
At TheApostrophe, our typical Nigeria readiness work focuses on:
CTD-aligned dossier build + internal peer review
Stability + specification consistency checks (before NAFDAC does)
Artwork/label + claims compliance to reduce deficiency cycles
If you’re evaluating Nigeria seriously, I suggest a short working call to map:
which SKUs are truly “Nigeria-ready” today
what will trigger preventable NAFDAC queries in your current document set
a phased submission plan that protects timeline + cashflow
Nigeria Regulatory Overview: * None [1]
https://theapostrophe.in/country/nigeria-pharma-nutra-registration*
Would you be open to a quick 30-minute call this week?
Warm regards,
Purva Shah
Founder – TheApostrophe
[email protected] [email protected]
+91 97144 85551
Main%20Banner [3]
www.theapostrophe.in [2]
blank [4]
[1] https://vinculum.odoo.com/r/73P/m/111984
[2] https://vinculum.odoo.com/r/ApB/m/111984
[3]
https://vinculum.odoo.com/web/image/791-cd3533b3/Main%20Banner.png?access_token=333d7cbc-51ee-4828-aefe-56d612298804
[4]
https://vinculum.odoo.com/mail/track/98358/094c5d98cd51a04ec084c76478743a38c9e76c014f1cbc556e46afb08b00793a/blank.gif
